JP5661791B2 - Ｎ−アシル環状アミン誘導体またはその医薬上許容される塩 - Google Patents
Ｎ−アシル環状アミン誘導体またはその医薬上許容される塩 Download PDFInfo
- Publication number
- JP5661791B2 JP5661791B2 JP2012541257A JP2012541257A JP5661791B2 JP 5661791 B2 JP5661791 B2 JP 5661791B2 JP 2012541257 A JP2012541257 A JP 2012541257A JP 2012541257 A JP2012541257 A JP 2012541257A JP 5661791 B2 JP5661791 B2 JP 5661791B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- optionally substituted
- substituted
- saturated heterocyclic
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(C1)*1*(CC(*)C*1CCC(C)CC1)C(NC)=O Chemical compound CC(C1)*1*(CC(*)C*1CCC(C)CC1)C(NC)=O 0.000 description 13
- AXIIEOPSQHRYCU-UHFFFAOYSA-N CN(C1)Cc2c1cccc2 Chemical compound CN(C1)Cc2c1cccc2 AXIIEOPSQHRYCU-UHFFFAOYSA-N 0.000 description 2
- VZWXIQHBIQLMPN-UHFFFAOYSA-N C(C1)COc2c1cccc2 Chemical compound C(C1)COc2c1cccc2 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- UWYZHKAOTLEWKK-UHFFFAOYSA-N C(CNC1)c2c1cccc2 Chemical compound C(CNC1)c2c1cccc2 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 1
- HEBMCVBCEDMUOF-UHFFFAOYSA-N C(COC1)c2c1cccc2 Chemical compound C(COC1)c2c1cccc2 HEBMCVBCEDMUOF-UHFFFAOYSA-N 0.000 description 1
- IRFSXVIRXMYULF-UHFFFAOYSA-N C1Nc(cccc2)c2C=C1 Chemical compound C1Nc(cccc2)c2C=C1 IRFSXVIRXMYULF-UHFFFAOYSA-N 0.000 description 1
- YRLORWPBJZEGBX-UHFFFAOYSA-N C1Nc(cccc2)c2OC1 Chemical compound C1Nc(cccc2)c2OC1 YRLORWPBJZEGBX-UHFFFAOYSA-N 0.000 description 1
- YBBLSBDJIKMXNQ-UHFFFAOYSA-N C1Nc(cccc2)c2SC1 Chemical compound C1Nc(cccc2)c2SC1 YBBLSBDJIKMXNQ-UHFFFAOYSA-N 0.000 description 1
- SFLGSKRGOWRGBR-UHFFFAOYSA-N C1OCc2c1cccc2 Chemical compound C1OCc2c1cccc2 SFLGSKRGOWRGBR-UHFFFAOYSA-N 0.000 description 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N C1Oc(cccc2)c2O1 Chemical compound C1Oc(cccc2)c2O1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- BNBQRQQYDMDJAH-UHFFFAOYSA-N C1Oc(cccc2)c2OC1 Chemical compound C1Oc(cccc2)c2OC1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 description 1
- XBTKZTYHSAHPOO-UHFFFAOYSA-N CC(C)(C)OC(N1C(CCN(CC2)CCC2C2C(C=CCC3)=C3NC2)CCOCC1)=O Chemical compound CC(C)(C)OC(N1C(CCN(CC2)CCC2C2C(C=CCC3)=C3NC2)CCOCC1)=O XBTKZTYHSAHPOO-UHFFFAOYSA-N 0.000 description 1
- OGPMGJVMGNBOSX-UHFFFAOYSA-N CC(C)(C=C1)C=CC(C(N2)=O)=C1C2=O Chemical compound CC(C)(C=C1)C=CC(C(N2)=O)=C1C2=O OGPMGJVMGNBOSX-UHFFFAOYSA-N 0.000 description 1
- MLWJVKQHISEUES-UHFFFAOYSA-N CC1(C)C=CC(NC(C2)=O)=C2C=C1 Chemical compound CC1(C)C=CC(NC(C2)=O)=C2C=C1 MLWJVKQHISEUES-UHFFFAOYSA-N 0.000 description 1
- XVFIRDMIATWJDW-UHFFFAOYSA-N CC1(C)C=CC(NC(C2)=S)=C2C=C1 Chemical compound CC1(C)C=CC(NC(C2)=S)=C2C=C1 XVFIRDMIATWJDW-UHFFFAOYSA-N 0.000 description 1
- FWTYHZFXJJNLJG-UHFFFAOYSA-N CC1(C)C=CC(NCC2)=C2C=C1 Chemical compound CC1(C)C=CC(NCC2)=C2C=C1 FWTYHZFXJJNLJG-UHFFFAOYSA-N 0.000 description 1
- CPJIWEILLMHNBY-UHFFFAOYSA-N CC1(C)C=CC(NCCC2)=C2C=C1 Chemical compound CC1(C)C=CC(NCCC2)=C2C=C1 CPJIWEILLMHNBY-UHFFFAOYSA-N 0.000 description 1
- VVKNVMKHRIKMAZ-UHFFFAOYSA-N CN(C(C1)=O)c(cccc2)c2S1(=O)=O Chemical compound CN(C(C1)=O)c(cccc2)c2S1(=O)=O VVKNVMKHRIKMAZ-UHFFFAOYSA-N 0.000 description 1
- RSQUAQMIGSMNNE-UHFFFAOYSA-N CN(C(C1)=O)c2c1cccc2 Chemical compound CN(C(C1)=O)c2c1cccc2 RSQUAQMIGSMNNE-UHFFFAOYSA-N 0.000 description 1
- GRDNENMVSPDQBD-UHFFFAOYSA-N CN(C(CC1)=O)c2c1cccc2 Chemical compound CN(C(CC1)=O)c2c1cccc2 GRDNENMVSPDQBD-UHFFFAOYSA-N 0.000 description 1
- FUKUPBBTZUYTPJ-UHFFFAOYSA-N CN(CC1)C(C(C2CC2)[IH]C)c2c1nc[nH]2 Chemical compound CN(CC1)C(C(C2CC2)[IH]C)c2c1nc[nH]2 FUKUPBBTZUYTPJ-UHFFFAOYSA-N 0.000 description 1
- WIBNJAMPVWJLAL-UHFFFAOYSA-N CN(CC1)C(C2=CC2)c2c1cccn2 Chemical compound CN(CC1)C(C2=CC2)c2c1cccn2 WIBNJAMPVWJLAL-UHFFFAOYSA-N 0.000 description 1
- IXEUYAHNQXAWNT-UHFFFAOYSA-N CN(CC1)Cc2c1[nH]cn2 Chemical compound CN(CC1)Cc2c1[nH]cn2 IXEUYAHNQXAWNT-UHFFFAOYSA-N 0.000 description 1
- WHPCVAGAAFZOMZ-UHFFFAOYSA-N CN(CC1)Cc2c1[s]cc2 Chemical compound CN(CC1)Cc2c1[s]cc2 WHPCVAGAAFZOMZ-UHFFFAOYSA-N 0.000 description 1
- KFHOHLYZHRZLBP-UHFFFAOYSA-N CN(CC1)Cc2c1cc[o]2 Chemical compound CN(CC1)Cc2c1cc[o]2 KFHOHLYZHRZLBP-UHFFFAOYSA-N 0.000 description 1
- XKEHOCBCGRWQIK-UHFFFAOYSA-N CN(CC1)Cc2c1cc[s]2 Chemical compound CN(CC1)Cc2c1cc[s]2 XKEHOCBCGRWQIK-UHFFFAOYSA-N 0.000 description 1
- KYXSVGVQGFPNRQ-UHFFFAOYSA-N CN(CC1)Cc2c1cccc2 Chemical compound CN(CC1)Cc2c1cccc2 KYXSVGVQGFPNRQ-UHFFFAOYSA-N 0.000 description 1
- USIQCFLYYCORLT-UHFFFAOYSA-N CN(CC1)Cc2c1cn[nH]2 Chemical compound CN(CC1)Cc2c1cn[nH]2 USIQCFLYYCORLT-UHFFFAOYSA-N 0.000 description 1
- GVFLVRHBRAMVAW-UHFFFAOYSA-N CN(CC1)Cc2c1cncc2 Chemical compound CN(CC1)Cc2c1cncc2 GVFLVRHBRAMVAW-UHFFFAOYSA-N 0.000 description 1
- LPEBNANSFHMRDN-UHFFFAOYSA-N CN(CC1)Cc2c1nc[o]2 Chemical compound CN(CC1)Cc2c1nc[o]2 LPEBNANSFHMRDN-UHFFFAOYSA-N 0.000 description 1
- JSYKQYFGEPJWQB-UHFFFAOYSA-N CN(CC1)Cc2c1nc[s]2 Chemical compound CN(CC1)Cc2c1nc[s]2 JSYKQYFGEPJWQB-UHFFFAOYSA-N 0.000 description 1
- DPDLJBOAQCWAOD-UHFFFAOYSA-N CN(CC1)c(cccc2)c2S1(=O)=O Chemical compound CN(CC1)c(cccc2)c2S1(=O)=O DPDLJBOAQCWAOD-UHFFFAOYSA-N 0.000 description 1
- MITVTGJIJSIASP-UHFFFAOYSA-N CN(CCc1c2cccc1)/C2=[O]/C=C Chemical compound CN(CCc1c2cccc1)/C2=[O]/C=C MITVTGJIJSIASP-UHFFFAOYSA-N 0.000 description 1
- JHMBTUMIVBSJFS-UHFFFAOYSA-N CN(Cc1c2cccc1)C2=O Chemical compound CN(Cc1c2cccc1)C2=O JHMBTUMIVBSJFS-UHFFFAOYSA-N 0.000 description 1
- LLSYLGPOUYXVKI-UHFFFAOYSA-N CN(Cc1c2nccc1)C2=C Chemical compound CN(Cc1c2nccc1)C2=C LLSYLGPOUYXVKI-UHFFFAOYSA-N 0.000 description 1
- DDYHWAGZGNBPGX-UHFFFAOYSA-N CN1Cc2cnccc2C1 Chemical compound CN1Cc2cnccc2C1 DDYHWAGZGNBPGX-UHFFFAOYSA-N 0.000 description 1
- YJRQBOOMJGYUPI-UHFFFAOYSA-N CN1c(cccc2)c2OCC1 Chemical compound CN1c(cccc2)c2OCC1 YJRQBOOMJGYUPI-UHFFFAOYSA-N 0.000 description 1
- DBJMEBUKQVZWMD-UHFFFAOYSA-N CN1c(cccc2)c2OCC1=O Chemical compound CN1c(cccc2)c2OCC1=O DBJMEBUKQVZWMD-UHFFFAOYSA-N 0.000 description 1
- SHUQPYGJXCEBIM-UHFFFAOYSA-N CN1c(cccc2)c2SCC1=O Chemical compound CN1c(cccc2)c2SCC1=O SHUQPYGJXCEBIM-UHFFFAOYSA-N 0.000 description 1
- DMFIMSDAAXTVBY-UHFFFAOYSA-N CS(C1)(c(cccc2)c2NC1=S)(O)=O Chemical compound CS(C1)(c(cccc2)c2NC1=S)(O)=O DMFIMSDAAXTVBY-UHFFFAOYSA-N 0.000 description 1
- DZUJQDAVLLFRSJ-CPJSRVTESA-N C[C@@H](CC[C@H]1CCN(CC2)CCC2C(c(cc2)ccc2F)=O)N1C(c1cc(ccc(C)c2)c2[nH]1)=O Chemical compound C[C@@H](CC[C@H]1CCN(CC2)CCC2C(c(cc2)ccc2F)=O)N1C(c1cc(ccc(C)c2)c2[nH]1)=O DZUJQDAVLLFRSJ-CPJSRVTESA-N 0.000 description 1
- LWZIUCRNLQRNNH-UHFFFAOYSA-N Cc1cccc(C=C2)c1N(C)/C2=[O]/c1ccc(CC(N(C)C2)=O)c2c1 Chemical compound Cc1cccc(C=C2)c1N(C)/C2=[O]/c1ccc(CC(N(C)C2)=O)c2c1 LWZIUCRNLQRNNH-UHFFFAOYSA-N 0.000 description 1
- MGZGPQCRWVOGFE-UHFFFAOYSA-N O=C(C1)NCc2c1cccc2 Chemical compound O=C(C1)NCc2c1cccc2 MGZGPQCRWVOGFE-UHFFFAOYSA-N 0.000 description 1
- YIWUEDSIYPTYEF-UHFFFAOYSA-N O=C(C1)Nc(cccc2)c2S1(=O)=O Chemical compound O=C(C1)Nc(cccc2)c2S1(=O)=O YIWUEDSIYPTYEF-UHFFFAOYSA-N 0.000 description 1
- TZOYXRMEFDYWDQ-UHFFFAOYSA-N O=C(CC1)Nc2c1cccc2 Chemical compound O=C(CC1)Nc2c1cccc2 TZOYXRMEFDYWDQ-UHFFFAOYSA-N 0.000 description 1
- YWPMKTWUFVOFPL-UHFFFAOYSA-N O=C1NCCc2c1cccc2 Chemical compound O=C1NCCc2c1cccc2 YWPMKTWUFVOFPL-UHFFFAOYSA-N 0.000 description 1
- PXZQEOJJUGGUIB-UHFFFAOYSA-N O=C1NCc2c1cccc2 Chemical compound O=C1NCc2c1cccc2 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N O=C1Nc(cccc2)c2C=C1 Chemical compound O=C1Nc(cccc2)c2C=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- QRCGFTXRXYMJOS-UHFFFAOYSA-N O=C1Nc(cccc2)c2OC1 Chemical compound O=C1Nc(cccc2)c2OC1 QRCGFTXRXYMJOS-UHFFFAOYSA-N 0.000 description 1
- GTFMIJNXNMDHAB-UHFFFAOYSA-N O=C1Nc(cccc2)c2SC1 Chemical compound O=C1Nc(cccc2)c2SC1 GTFMIJNXNMDHAB-UHFFFAOYSA-N 0.000 description 1
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N O=C1Oc(cccc2)c2N1 Chemical compound O=C1Oc(cccc2)c2N1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 1
- XIWPSQOMKUXAGI-CYBMUJFWSA-N O=CC[C@H]1N(Cc2ccccc2)CCOC1 Chemical compound O=CC[C@H]1N(Cc2ccccc2)CCOC1 XIWPSQOMKUXAGI-CYBMUJFWSA-N 0.000 description 1
- XEWSSOYBTBEUPW-UHFFFAOYSA-N S=C(C1)NCc2c1cccc2 Chemical compound S=C(C1)NCc2c1cccc2 XEWSSOYBTBEUPW-UHFFFAOYSA-N 0.000 description 1
- UMHLZGJTGWFCGD-UHFFFAOYSA-N S=C(CC1)Nc2c1cccc2 Chemical compound S=C(CC1)Nc2c1cccc2 UMHLZGJTGWFCGD-UHFFFAOYSA-N 0.000 description 1
- CMTSCLKCQBPLSH-UHFFFAOYSA-N S=C(c1c2cccc1)NC2=S Chemical compound S=C(c1c2cccc1)NC2=S CMTSCLKCQBPLSH-UHFFFAOYSA-N 0.000 description 1
- IRXWBCKPECPALY-UHFFFAOYSA-N S=C1NCCc2c1cccc2 Chemical compound S=C1NCCc2c1cccc2 IRXWBCKPECPALY-UHFFFAOYSA-N 0.000 description 1
- KXZSVYHFYHTNBI-UHFFFAOYSA-N S=C1Nc(cccc2)c2C=C1 Chemical compound S=C1Nc(cccc2)c2C=C1 KXZSVYHFYHTNBI-UHFFFAOYSA-N 0.000 description 1
- MFPHAWZIKUKQOU-UHFFFAOYSA-N S=C1Nc(cccc2)c2OC1 Chemical compound S=C1Nc(cccc2)c2OC1 MFPHAWZIKUKQOU-UHFFFAOYSA-N 0.000 description 1
- AQWCHSYEHJCCNU-UHFFFAOYSA-N S=C1Nc(cccc2)c2SC1 Chemical compound S=C1Nc(cccc2)c2SC1 AQWCHSYEHJCCNU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012541257A JP5661791B2 (ja) | 2010-03-11 | 2011-03-11 | Ｎ−アシル環状アミン誘導体またはその医薬上許容される塩 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010054177 | 2010-03-11 | ||
| JP2010054177 | 2010-03-11 | ||
| JP2010285844 | 2010-12-22 | ||
| JP2010285844 | 2010-12-22 | ||
| JP2012541257A JP5661791B2 (ja) | 2010-03-11 | 2011-03-11 | Ｎ−アシル環状アミン誘導体またはその医薬上許容される塩 |
| PCT/JP2011/056497 WO2011111875A1 (en) | 2010-03-11 | 2011-03-11 | N-acyl cyclic amine derivative or pharmaceutically acceptable salt thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013522165A JP2013522165A (ja) | 2013-06-13 |
| JP2013522165A5 JP2013522165A5 (enExample) | 2014-03-13 |
| JP5661791B2 true JP5661791B2 (ja) | 2015-01-28 |
Family
ID=44563664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012541257A Expired - Fee Related JP5661791B2 (ja) | 2010-03-11 | 2011-03-11 | Ｎ−アシル環状アミン誘導体またはその医薬上許容される塩 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8541585B2 (enExample) |
| EP (1) | EP2545046A4 (enExample) |
| JP (1) | JP5661791B2 (enExample) |
| KR (1) | KR101756495B1 (enExample) |
| CN (1) | CN102884059B (enExample) |
| AU (1) | AU2011225095C1 (enExample) |
| CA (1) | CA2792539C (enExample) |
| TW (1) | TWI475015B (enExample) |
| WO (1) | WO2011111875A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102180872B (zh) * | 2011-04-01 | 2014-04-02 | 华中科技大学 | [1,3,4]噁二唑类衍生物及其应用 |
| CN104892589A (zh) * | 2014-03-07 | 2015-09-09 | 中国科学院上海药物研究所 | 一类杂环化合物、其制备方法和用途 |
| PL245933B1 (pl) | 2014-07-04 | 2024-11-04 | Inst Farmakologii Polskiej Akademii Nauk | (Chinolino lub izochinolino) sulfonamidy amin cyklicznych, kompozycja je zawierająca, sposób ich wytwarzania oraz ich zastosowanie medyczne |
| CN105315267B (zh) * | 2014-07-30 | 2019-06-04 | 江苏恩华药业股份有限公司 | 一种酰胺类衍生物及其应用 |
| JP2019059672A (ja) * | 2015-12-28 | 2019-04-18 | 大日本住友製薬株式会社 | 治療抵抗性うつ病等の治療薬 |
| UY39569A (es) | 2020-12-17 | 2022-07-29 | Astrazeneca Ab | N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)- quinolin-4-carboxamidas |
| JP7655885B2 (ja) * | 2021-06-30 | 2025-04-02 | 住友ファーマ株式会社 | 脂肪族酸アミド誘導体を含有する医薬組成物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3133061A (en) | 1962-11-13 | 1964-05-12 | Sterling Drug Inc | Piperidine carboxamides and derivatives thereof |
| FR2285883A1 (fr) | 1974-09-30 | 1976-04-23 | Cerm Cent Europ Rech Mauvernay | Nouveaux composes chimiques a activite bronchospasmolytique et antitussive, et procede pour leur obtention |
| JPH08502474A (ja) * | 1992-10-07 | 1996-03-19 | メルク エンド カンパニー インコーポレーテッド | トコリティックオキシトシンレセプターアンタゴニスト |
| JP3162572B2 (ja) | 1993-04-28 | 2001-05-08 | 住友製薬株式会社 | インドロイルグアニジン誘導体 |
| JPH08208602A (ja) | 1994-10-18 | 1996-08-13 | Sumitomo Pharmaceut Co Ltd | インドロイルグアニジン誘導体 |
| FR2729954B1 (fr) | 1995-01-30 | 1997-08-01 | Sanofi Sa | Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant |
| US5861417A (en) * | 1996-12-19 | 1999-01-19 | Hoechst Marion Roussel, Inc. | Heterocyclic substituted pyrrolidine amide derivatives |
| US6166037A (en) * | 1997-08-28 | 2000-12-26 | Merck & Co., Inc. | Pyrrolidine and piperidine modulators of chemokine receptor activity |
| UA58476C2 (uk) | 1997-10-09 | 2003-08-15 | Санофі-Сентелябо | Похідні 8-азабіцикло[3.2.1]октан-3-метанаміну, фармацевтична композиція та лікарський засіб |
| US7164024B2 (en) | 2001-04-20 | 2007-01-16 | Banyu Pharmaceutical Co., Ltd. | Benzimidazolone derivatives |
| FR2824828B1 (fr) * | 2001-05-21 | 2005-05-20 | Sanofi Synthelabo | Nouveaux derives de piperidinecarboxamide, un procede pour leur preparation et les compositions pharmaceutiques les contenant |
| AU2002351733A1 (en) | 2001-12-19 | 2003-06-30 | H. Lundbeck A/S | 3,4-dihydro-1h-isoquinoloin-2-yl-derivatives |
| MXPA06007654A (es) * | 2003-12-31 | 2006-09-04 | Warner Lambert Co | Derivados de piperidina n-sustituidos. |
| WO2006033943A2 (en) | 2004-09-17 | 2006-03-30 | Exelixis, Inc | Pyrazole kinase modulators and methods of use |
| WO2007061741A2 (en) | 2005-11-17 | 2007-05-31 | Arena Pharmaceuticals, Inc. | Modulators of the h3 receptor useful for the treatment of disorders related thereto |
| JP5176281B2 (ja) | 2006-03-23 | 2013-04-03 | 大日本印刷株式会社 | リチウムイオン電池 |
-
2011
- 2011-03-11 CN CN201180023571.1A patent/CN102884059B/zh not_active Expired - Fee Related
- 2011-03-11 TW TW100108373A patent/TWI475015B/zh not_active IP Right Cessation
- 2011-03-11 CA CA2792539A patent/CA2792539C/en not_active Expired - Fee Related
- 2011-03-11 JP JP2012541257A patent/JP5661791B2/ja not_active Expired - Fee Related
- 2011-03-11 AU AU2011225095A patent/AU2011225095C1/en not_active Ceased
- 2011-03-11 WO PCT/JP2011/056497 patent/WO2011111875A1/en not_active Ceased
- 2011-03-11 EP EP11753530.2A patent/EP2545046A4/en not_active Withdrawn
- 2011-03-11 KR KR1020127024562A patent/KR101756495B1/ko not_active Expired - Fee Related
- 2011-03-11 US US13/505,161 patent/US8541585B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130016234A (ko) | 2013-02-14 |
| US20120214790A1 (en) | 2012-08-23 |
| CA2792539C (en) | 2017-04-18 |
| JP2013522165A (ja) | 2013-06-13 |
| AU2011225095B2 (en) | 2016-05-19 |
| CN102884059B (zh) | 2015-08-26 |
| EP2545046A4 (en) | 2015-03-25 |
| TWI475015B (zh) | 2015-03-01 |
| WO2011111875A1 (en) | 2011-09-15 |
| EP2545046A1 (en) | 2013-01-16 |
| AU2011225095A1 (en) | 2012-09-27 |
| AU2011225095C1 (en) | 2017-01-19 |
| US8541585B2 (en) | 2013-09-24 |
| TW201139413A (en) | 2011-11-16 |
| KR101756495B1 (ko) | 2017-07-10 |
| CA2792539A1 (en) | 2011-09-15 |
| CN102884059A (zh) | 2013-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201311674A (zh) | 吲唑－及吡咯并吡啶－衍生物及其醫藥用途 | |
| CN113557235A (zh) | 用于药物治疗的杂环化合物 | |
| IL275058B1 (en) | Sulphonyl urea derivatives as nlrp3 inflammasome modulators | |
| JP2013522165A (ja) | Ｎ−アシル環状アミン誘導体またはその医薬上許容される塩 | |
| CN102239168B (zh) | 作为h3调节剂的取代的哌啶螺吡咯烷酮和哌啶酮 | |
| AU2021201424B2 (en) | Aminopyridine derivatives and their use as selective alk-2 inhibitors | |
| WO2001070689A1 (en) | DIPHENYLALKYLAMINE DERIVATIVES USEFUL AS OPIOID δ RECEPTOR AGONISTS | |
| JP5715605B2 (ja) | Ｎ−アシル環状アミン誘導体またはその医薬上許容される塩からなる医薬 | |
| BR112021004310A2 (pt) | indazolcarboxamidas como inibidores de cinase | |
| CA3234429A1 (en) | Ras inhibitors, compositions and methods of use thereof | |
| IL303942A (en) | An aromatic heterocyclic substance, a pharmaceutical composition comprising the same, and their use | |
| JP2014506905A (ja) | 新規なベンゾジオキソールピペリジン化合物 | |
| JPWO2013039057A1 (ja) | ピロリジン−３−イル酢酸誘導体 | |
| KR101575703B1 (ko) | 모틸린 수용체에 대해 작용제 활성을 가진 옥시인돌 유도체 | |
| JP2009523747A (ja) | α７ニコチン性アセチルコリン受容体のモジュレーターおよびその治療上の使用 | |
| WO2019129025A1 (zh) | 四氢吡咯类化合物、其制备方法、药物组合物及用途 | |
| JP2013523806A (ja) | スルタム化合物 | |
| US20080015214A1 (en) | 3-piperidin-4-yl-indole orl-1 receptor modulators | |
| TWI912370B (zh) | 芳香雜環類化合物、藥物組合物及其應用 | |
| CN118076599A (zh) | 二噁嗪类及其在治疗gba相关疾病中的用途 | |
| CN120112526A (zh) | 一种egfr降解剂及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140123 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140123 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141104 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141203 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5661791 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |